Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Research analysts at Wedbush upped their FY2021 earnings per share estimates for Intercept Pharmaceuticals in a research note issued on Friday. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will earn $10.38 per share for the year, up from their prior estimate of $9.98. Wedbush currently has a “Outperform” rating and a $253.00 target price on the stock. Wedbush also issued estimates for Intercept Pharmaceuticals’ FY2022 earnings at $21.42 EPS.
Several other research analysts have also commented on the company. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 19th. BidaskClub raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 17th. BMO Capital Markets boosted their price target on Intercept Pharmaceuticals from $152.00 to $155.00 and gave the stock an “outperform” rating in a research report on Thursday, February 15th. Oppenheimer reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, February 15th. Finally, Cantor Fitzgerald set a $58.00 price target on Intercept Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, February 14th. Four research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $128.75.
Intercept Pharmaceuticals (ICPT) traded down $0.95 on Monday, hitting $66.30. The stock had a trading volume of 862,607 shares, compared to its average volume of 945,600. The company has a market cap of $1,740.00, a price-to-earnings ratio of -4.59 and a beta of -1.92. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 21.71. Intercept Pharmaceuticals has a 52-week low of $51.05 and a 52-week high of $135.59.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.39) by ($1.04). The firm had revenue of $37.69 million during the quarter, compared to analysts’ expectations of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 267.95% and a negative net margin of 275.18%. Intercept Pharmaceuticals’s quarterly revenue was up 173.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($4.84) earnings per share.
Large investors have recently made changes to their positions in the stock. DSC Advisors L.P. acquired a new position in Intercept Pharmaceuticals during the 4th quarter valued at about $204,000. Amalgamated Bank acquired a new position in Intercept Pharmaceuticals during the 4th quarter valued at about $209,000. Virtu Financial LLC acquired a new position in Intercept Pharmaceuticals during the 4th quarter valued at about $234,000. Oppenheimer & Co. Inc. increased its position in Intercept Pharmaceuticals by 145.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 2,833 shares in the last quarter. Finally, Wedbush Securities Inc. acquired a new position in Intercept Pharmaceuticals during the 4th quarter valued at about $331,000. 74.33% of the stock is currently owned by institutional investors.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.